{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003872","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.231346+00:00","generated_at":"2026-06-18T01:44:42.435498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M","bullets":["Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.","Full-year core business revenue $39.6M, up 26%; cell therapy segment grew 33%.","Net loss $23.6M vs $19.1M; EBITDA loss $24.8M; cash and equivalents $227.3M.","18 active SPL partnerships; potential pre-commercial milestones >$1.55B.","2023 guidance: total revenue growth 21-26%, core growth 20-25%, SPL program revenue ~$6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003872","json":"https://secwatch.observer/filing/0001558370-23-003872.json","markdown":"https://secwatch.observer/filing/0001558370-23-003872.md","text":"https://secwatch.observer/filing/0001558370-23-003872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/0001558370-23-003872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/mxct-20230315x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:44:42.435498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee95a71abfe3cef0538b445b65d0487f4c6e1f76","claim":"MAXCYTE, INC. updated its the quarter and year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On March 15, 2023, MaxCyte, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023003872/0001558370-23-003872-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}